Results 181 to 190 of about 260,779 (356)
Proteomic and phosphoproteomic analyses were performed on lung adenocarcinoma (LUAD) tumors with EGFR, KRAS, or EML4–ALK alterations and wild‐type cases. Distinct protein expression and phosphorylation patterns were identified, especially in EGFR‐mutated tumors. Key altered pathways included vesicle transport and RNA splicing.
Fanni Bugyi +12 more
wiley +1 more source
Mohammad Taheri,1,* Ghazaleh Azimi,2,* Arezou Sayad,2 Mehrdokht Mazdeh,3 Shahram Arsang-Jang,4,5 Mir Davood Omrani,5 Soudeh Ghafori-Fard2 1Student Research Committee, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 2Department of Medical ...
Taheri M +6 more
doaj
Peroxisome Proliferator-Activated Receptor-δ Genotype Influences Metabolic Phenotype and May Influence Lipid Response to Statin Therapy in Humans: A Genetics of Diabetes Audit and Research Tayside Study [PDF]
Lindsay Burch +9 more
openalex +1 more source
Genetic toxicology and genetically active environmental factors
A. I. Zhussupova +2 more
openaire +2 more sources
Objectives and activities of the Genetic Alliance [PDF]
M E Davidson, J Weiss
openaire +2 more sources
Targeting of PTP4A3 overexpression sensitises HGSOC cells towards chemotherapeutic drugs
In HGSOC with normal KRAS expression, high PTP4A3 expression regulates autophagy activation. Conversely, in HGSOC with high KRAS expression, KRAS dictates autophagy control, and PTP4A3 is not required. When high PTP4A3 expression is inhibited, HGSOC cells are preferentially sensitised towards DNA‐damaging agents.
Ana López‐Garza +3 more
wiley +1 more source
Genetic evidence informs the direction of therapeutic modulation in drug development. [PDF]
Chen R +10 more
europepmc +1 more source
The Relationship between Peroxisome Proliferator-Activated Receptor-γ and Renin: A Human Genetics Study [PDF]
Patricia Underwood +11 more
openalex +1 more source
Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh +5 more
wiley +1 more source

